Session Chair Profile

Co-founder and SVP, BD & Strategy, Helix

Justin is a co-founder and SVP of Business Development & Strategy at Helix, a population genomics company with a mission to empower every person to improve their life through DNA. Helix’s end-to-end population health solution enables health systems to integrate genomic information on a population scale to improve outcomes, lower costs, increase patient engagement, and accelerate research. Prior to Helix, Justin was a Vice President in the healthcare group at Warburg Pincus, a global private equity firm focused on growth investing. Earlier in his career, he also spent time at the Boston Consulting Group, where he worked with a variety of companies in the tech and healthcare industries, and Onyx Pharmaceuticals. Justin holds a B.S. in Chemical Engineering and a M.S. in Bioengineering from Stanford University. He also received a J.D. from Stanford Law School and an M.B.A. from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.

 Session Abstract – PMWC 2020 Silicon Valley

Genomics is at an inflection point. Dramatic declines in sequencing costs and significant advances in our understanding of the genome means we’re moving closer to a world where genomics is the standard of care. Evidence is emerging that population-level screening drives meaningful clinical impact with ~1 in 30 people having an actionable result, but up to 90% of them are missed under current guidelines. Leading health systems are working to solve this by offering broad genetic screening to their communities. But questions remain about how to handle results when millions of people are screened. The tools and services to enable this are critical, including patient- and physician-friendly results, educational materials, and genetic counseling. In this session, healthcare leaders will discuss how they scale return of results and improve outcomes for their communities.